Measurement of Activated Factor IX in Factor IX Concentrates: Correlation with In Vivo Thrombogenicity

Summary

Current in vitro tests for thrombogenicity of FIX concentrates used for prothrombin complex concentrates (PCCs), are of little value when applied to high purity FIX (HP FIXs). In the present study, we have developed a chromogenic assay for activated FIX (FIXa) and evaluated its ability to predict in vivo thrombogenic potential of HP FIXs in a modified Wessler stasis model. Among the HP FIXs, only 1 out of 7 products had no detectable FIXa; this product also showed no in vivo thrombogenicity. In the other 6 products, FIXa content ranged from 0.15–1.2 U/1000 iu FIX, and all showed some evidence of in vivo thrombogenicity, with mean thrombus scores ranging from 0.25–4. There was a significant positive correlation (r = 0.55, p <0.02) between FIXa levels and in vivo thrombogenicity of HP FIXs. NAPTT data were not significantly correlated with the in vivo results and the TFCT also showed no direct correlation with the mean thrombus score. These results indicate that HP FIXs may still carry a small residual thrombotic risk and measurement of FIXa content of these products may be a better predictor of thrombogenicity than the current in vitro tests.

• References

• 1 Kasper CK. Thromboembolic complications. Thrombos Diath Haemorrh 1975; 33: 640-644
• 2 Lusher JM. Thrombogenicity associated with Factor IX Complex Concentrates. Seminars in Hematology 1991; 28 Suppl (Suppl. 06) 3-5
• 3 Kingdon HS, Lundblad RL, Veltkamp JJ, Aronson DL. Potentially throm-bogenic materials in factor IX concentrates. Thrombos Diath Haemorrh 1975; 33: 617-631
• 4 Hultin MB. Activated clotting factors in factor IX concentrates. Blood 1979; 54: 1028-1038
• 5 Seligsohn U, Kasper CK, Østerud B, Rapaport SI. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828-837
• 6 Giles AR, Nesheim ME, Hoogendoom H, Tracy PB, Mann KG. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits. Blood 1982; 59: 401-407
• 7 Prowse CV, Williams AE. A comparison of the in vitro and in vivo throm- bogenic activity of factor IX concentrates using stasis (Wessler) and nonstasis rabbit models. Thromb Haemost 1980; 44: 81-86
• 8 Menache D, Behre HE, Orthner CL, Nunez H, Anderson HD, Triantaphyl-lopoulos DC, Kosow DP. Coagulation factor IX concentrate: Method of preparation and assessment of potential in vivo thrombogenicity in animal models. Blood 1984; 64: 1220-1227
• 9 Littlewood JD, Dawes J, Smith JK, Feldman PA, Haddon ME, McQuillan TA, Foster PR, Ferguson JM, Prowse CV. Studies on the effect of heat treatment on the thrombogenicity of factor IX concentrates in dogs. Br J Haem 1987; 65: 463-468
• 10 MacGregor IR, Ferguson JF, Dawes J, McLaughlin L, Prowse CV. Throm-bogenicity of a factor IX concentrate quantitated in a canine model. Blood Coagulation and Fibrinolysis 1990; 1: 23-30
• 11 Cash JD, Dalton RG, Middleton S, Smith JK. Studies on the thrombogeni- city of Scottish factor IX concentrates in dogs. Thromb Diath Haemorrh 1975; 33: 632-639
• 12 Hedner U, Nilsson IM, Bergentz SE. Various prothrombin complex concentrates and their effect upon coagulation and fibronolysis in vivo. Thromb Haemost 1976; 35: 386-395
• 13 Kim HC, McMillan CW, Gilbert CW, Bergman GE, Saidi P. Clinical experience of a new monoclonal antibody purified factor IX: Half-life, recovery, and safety in patients with hemophilia B. Seminars in Hematologyz 1990; 27 Suppl (Suppl. 02) 30-35
• 14 Herring SW, Abildgaard C, Shitanishi KT, Harrison J, Gendler S, Heldebrant CM. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety. J Lab Clin Med 1993; 121: 394-405
• 15 Hampton KK, Preston FE, Lowe GD O, Walker ID, Sampson B. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haem 1993; 84: 279-284
• 16 Ohga S, Saito M, Matsukazi A, Kai T, Ueda K. Disseminated intravascular coagulation in a patient with haemophilia B during factor IX replacement therapy. Br J Haem 1993; 84: 343-345
• 17 Elödi S, Váradi K. Activation of clotting factors in prothrombin complex concentrates as demonstrated by clotting assays for factor IXa and Xa. Thrombos Res 1978; 12: 797-807
• 18 Gitel SN, Stephenson RC, Wessler S. In vitro and in vivo correlation of clotting protease activity: Effect of heparin. Proc Natl Acad Sci USA 1977; 74: 3028-3032
• 19 Padilla A, Gray E, Pepper DS, Barrowcliffe TW. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the presence and absence of platelet factor 4 (PF4). Br J Haem 1992; 82: 406-413
• 20 Michalski C, Bal F, Burnouf T, Goudemand M. Large-scale production and properties of a solvent detergent treated factor IX concentrate from human plasma. Vox Sang 1988; 55: 202-210
• 21 Kirkwood TB L, Snape TJ. Biometric principles in clotting and clot lysis assays. Clin Lab Haemat 1980; 2: 155-167
• 22 Boisclair MD, Lane DA, Philippou H, Esnouf MP, Sheikh S, Hunt B, Smith KJ. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993; 82: 3350-3357
• 23 Burnouf T, Michalski C, Goudemand M, Huart JJ. Properties of a highly purified human factor IX:C therapeutic concentrate preparated by conventional chromatography. Vox Sang 1989; 57: 225-232
• 24 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990; 76: 2540-2545
• 25 Kemball-Cook G, Tubbs JE, Dawson NJ, Barrowcliffe TW. The behaviour of different factor VIII concentrates in a chromogenic factor X-activating system. Brit J Haematol 1993; 84: 273-278